The Food and Drug Administration (FDA) has approved Restasis MultiDose (cyclosporine ophthalmic emulsion 0.05%), a multi-dose, preservative-free preparation of Restasis. The patented unidirectional valve and air filter technology eliminates the need for a preservative.
Restasis, a calcineurin inhibitor immunosuppressant, is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
Restasis MultiDose will be available as 5.5mL in a 10mL bottle. Single-use, preservative-free vials of Restasis are currently available as well.
For more information visit Allergan.com.